Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 11/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335185 | 0.86 | ADRB3 (0.42) | ADRB3MAPTMEN1KMT2AF2 | |
| SCHEMBL6388761 | 0.75 | ADRB3 (0.46) | ADRB3MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL6388756 | 0.75 | ADRB3 (0.46) | ADRB3MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL6407593 | 0.71 | KCNH2 (0.40) | ADRB3MAPT | |
| SCHEMBL6343469 | 0.71 | KCNH2 (0.40) | ADRB3MAPT | |
| SCHEMBL6335927 | 0.68 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL29873770 | 0.67 | NAMPT (0.47) | MAPTMEN1KMT2ACYP3A4TSHR | |
| SCHEMBL6337763 | 0.67 | SSTR4 (0.41) | ADRB3KMT2APOLB | |
| SCHEMBL6284029 | 0.65 | FFAR4 (0.35) | ADRB3 | |
| SCHEMBL7716904 | 0.64 | AOC3 (0.36) | ADRB3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885MAPT 4302/4885MEN1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.